Literature DB >> 8320787

The lifetime cost of treating a person with HIV.

F J Hellinger1.   

Abstract

OBJECTIVE: To estimate the cost (total charges for services) of medical care for persons with human immunodeficiency virus (HIV) from the time of infection until death. DESIGN AND
SETTING: Data from the AIDS (acquired immunodeficiency syndrome) Cost and Service Utilization Survey were used. PATIENTS: Data from interviews conducted during the spring and early summer of 1992 with 1164 respondents with HIV were analyzed. The respondents were recruited at 26 sites (hospitals, clinics, and physicians' offices) in 10 cities. Billing data from a survey of providers also were used. OUTCOME MEASURES: Estimates of the mean occupancy time in each of four disease stages were obtained from the San Francisco Men's Health Study. These estimates were multiplied by the monthly cost in each stage and summed to derive a synthetic estimate of the lifetime medical care costs of treating a person with HIV.
RESULTS: It is estimated herein that the lifetime cost of treating a person with HIV from the time of infection until death is approximately $119,000. The estimated cost of care from HIV infection until the development of AIDS is $50,000, while the estimated cost from AIDS development until death is approximately $69,000. These estimates define upper bounds because they assume persons receive treatment continuously from the moment of infection until death.
CONCLUSIONS: This study found that the cost of treating a person with AIDS, which has risen rapidly in the past, has fallen as a result of a reduction in the use of inpatient hospital services.

Entities:  

Mesh:

Year:  1993        PMID: 8320787

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  58 in total

1.  Healthcare Economics in HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Cost effectiveness of combination HIV therapy: 3 years later.

Authors:  R D Moore
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 3.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

4.  Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria.

Authors:  Marion S Rauner
Journal:  Health Care Manag Sci       Date:  2002-04

5.  An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease.

Authors:  G G Liu; J Hay
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 6.  Current controversies in the treatment of HIV infection and AIDS. An economic perspective.

Authors:  S Petrou
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

7.  Combination antiretroviral therapy in HIV infection. An economic perspective.

Authors:  R D Moore; J G Bartlett
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 8.  Costs of illness in cost-effectiveness analysis. A review of the methodology.

Authors:  T A Hodgson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

9.  Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries.

Authors:  K Simpson; E J Hatziandreu; F Andersson; A Shakespeare; I Oleksy; A N Tosteson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

10.  Structures of care in the clinics of the HIV Research Network.

Authors:  Baligh R Yehia; Kelly A Gebo; Perrin B Hicks; P Todd Korthuis; Richard D Moore; Michelande Ridore; William Christopher Mathews
Journal:  AIDS Patient Care STDS       Date:  2008-12       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.